Cystic Fibrosis (CF) Carrier Testing at Eurofins NTD, LLC. helps identify couples who carry mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, causing cystic fibrosis.
This safe and convenient prenatal test, which can be performed at the same time as Down syndrome screening, enables healthcare providers to determine if a patient is at increased risk of having a child born with CF.
The American College of Obstetricians and Gynecologists (ACOG) recommends that CF carrier screening be offered to all couples seeking prenatal care, not just those with a personal or family history of the disease. Cystic fibrosis has a higher carrier frequency in Caucasians, but is found in all ethnicities, as seen in the table below*.
*ACOG Committee Opinion #325, 2005
**Cystic Fibrosis Foundation
DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. DNA extracted from a sample is tested for the 23 ACMG/ACOG recommended mutations plus an additional 16 polymorphisms within the Cystic Fibrosis Transmembrane Requlator (CFTR) gene. These mutations are screened for using the Luminex xTAG® Cystic Fibrosis 39 Kit v2 after multiplex polymerase chain reaction (PCR). The xTAG® Cystic Fibrosis 39 kit v2 has been cleared by the U.S. Food and Drug Administration (FDA) for use with human whole blood samples. The test result should always be interpreted in the context of clinical presentation and family history.